000 01510 a2200433 4500
005 20250517151216.0
264 0 _c20170608
008 201706s 0 0 eng d
022 _a1862-3514
024 7 _a10.1007/s11657-017-0336-1
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aIshiguro, Shigeo
245 0 0 _aThe clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease.
_h[electronic resource]
260 _bArchives of osteoporosis
_cDec 2017
300 _a44 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAged
650 0 4 _aAged, 80 and over
650 0 4 _aBone Density
_xdrug effects
650 0 4 _aBone Density Conservation Agents
_xadministration & dosage
650 0 4 _aDenosumab
_xadministration & dosage
650 0 4 _aDiphosphonates
_xadministration & dosage
650 0 4 _aFemale
650 0 4 _aFollow-Up Studies
650 0 4 _aGlucocorticoids
_xadverse effects
650 0 4 _aHumans
650 0 4 _aLumbar Vertebrae
_xdrug effects
650 0 4 _aLung Diseases
_xdrug therapy
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aOsteoporosis
_xchemically induced
650 0 4 _aProspective Studies
700 1 _aIto, Kentaro
700 1 _aNakagawa, Shigenori
700 1 _aHataji, Osamu
700 1 _aSudo, Akihiro
773 0 _tArchives of osteoporosis
_gvol. 12
_gno. 1
_gp. 44
856 4 0 _uhttps://doi.org/10.1007/s11657-017-0336-1
_zAvailable from publisher's website
999 _c27096055
_d27096055